Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)

Part of paid clinical trials in Charlottesville, Virginia.

Sponsor
University of Virginia
Study ID
NCT07213648
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MindTrails-Movement — BEHAVIORAL
    CBM-I training app with active CBM-I training condition
  • Waitlist Control — OTHER
    Version of MindTrails-Movement app including surveys and list of support resources but without active CBM-I training component

Study Details

The purpose of this study is to assess preliminary efficacy of a tailored cognitive bias modification for interpretation (CBM-I) app for reducing anxiety in Huntington's disease and Parkinson's disease.

Key Dates

Start date
Nov 20, 2025
Status verified
Nov 2025
Primary completion
Aug 31, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
136 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: MindTrails-Movement CBM-I Condition
    The intervention group (N=68) will include participants with Huntington's disease (N=34) and Parkinson's disease (N=34). Participants will download the MindTrails-Movement app with active CBM-I training condition and will be prompted to complete brief, daily CBM-I training sessions for a period of 6 weeks. They will complete surveys assessing mood symptoms and interpretation bias at baseline, end of week 2, end of week 4, and end of week 6 (end of intervention), then again at the end of week 10.
  • Other: Waitlist Control Condition
    The waitlist control group (N=68) will include participants with Huntington's disease (N=34) and Parkinson's disease (N=34). Participants will be asked to download a control version of the app that includes access to a list of support resources but does not include daily CBM-I training content. They will complete surveys assessing mood symptoms and interpretation bias at baseline, end of week 2, end of week 4, and end of week 6, and end of week 10. Waitlist control participants will be offered the opportunity to complete the intervention version of the app after they complete their final study assessments.

Primary Outcome Measure

Quality of Life in Neurological Disorders (NeuroQoL) Anxiety short form [ Time Frame: From baseline to end of week 6 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Univeristy of Virginia School of NursingCharlottesvilleVirginia22903
Jessie Gibson, PhD, RN
[email protected]
434-924-0107

Find similar trials in Charlottesville, VA

By condition
Huntington diseaseParkinson's disease
By specialty
NeurologyBrain disorders
By research site
Univeristy of Virginia School of Nursing· Charlottesville, VA

Related Studies